Khiron Receives Accreditation for UK Medical Cannabis Education and Partners with UK s Cellen Therapeutics to Improve Clinician Education
USA - English
Share this article
Share this article
UK medical professionals may now earn CPD credits through Khiron s medical cannabis education program
The Company has entered into a strategic partnership with Cellen Therapeutics, a leader in digital healthcare in the UK, to increase patient access via medical cannabis education
As a leading international medical cannabis educator, nearly 1,000 medical professionals in Latin America and the United Kingdom have registered for, or completed, Khiron Academy training
TORONTO, April 13, 2021 /PRNewswire/ - Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce it has received UK Continuing Professional Development ( CPD ) accredita
Khiron élargit sa gamme de produits au Royaume-Uni et améliore l accès des patients à ses produits
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Khiron Expands Product Offering in UK and Increases Patient Access
Following successful medical cannabis launch in Germany, Khiron 1/14, a high CBD flower is expected to be available in Q2/21 for UK patients
Khiron plans to introduce additional cannabis-based medical products with its registered strains, recently exported from Colombia to Europe
Supply chain improvements will increase availability of medical cannabis for patients in the United Kingdom
TORONTO, April 7, 2021 /PRNewswire/ Khiron Life Sciences Corp. ( Khiron or the Company ) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to provide an operational update with regards to its supply of EU-GMP medical cannabis products to the UK. To help alleviate bottlenecks and stock outs, the Company has established an offshore inventory of dried flower, for the express purpose of serving UK patients.
Khiron Becomes First Colombian Medical Cannabis Company to Export Live Cannabis Clones to Europe
Stocks Apr 6, 2021 • 7:39 AM EDT 4 MIN READ • By Michael Berger Share
Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to announce that the Company has successfully exported its registered Colombian cannabis strains, in the form of live clones, to Europe. This significant milestone represents the first shipment of medical cannabis live plant material to Europe from Colombia and is expected to accelerate access to European markets as the Company executes on its asset light growth strategy in the United Kingdom and Germany.
Khiron Sets A Milestone As First Colombian Medical Cannabis Company To Export To Europe Benzinga 2 hrs ago
This article is sponsored by Khiron Life Sciences.
Khiron Life Sciences (TSX.V: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) (“Khiron” or the “Company”) is a vertically integrated cannabis leader with core operations in Latin America and Europe. As cannabis legalization expands globally, Prohibition Partners’ stats predict by 2024 the European market will be worth nearly $2.5 billion, and many want in. Some companies have already taken steps to get their foot in the door, Khiron Life Sciences among them.
Popular Searches
Leading the Way Overseas
vimarsana © 2020. All Rights Reserved.